IMNM Q1 2022 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$12M

Net Income

-$12M

EPS (Diluted)

$-0.96

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$48M

Total Liabilities

$10M

Stockholders' Equity

$38M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$12M	-$4M	-199.1%
Net Income	-$12M	-$4M	-198.9%